
Georg Breier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6925694/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 1996, 380, 435-439.	13.7	3,776
2	Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature, 1992, 359, 845-848.	13.7	2,168
3	The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities. Journal of Biological Chemistry, 1996, 271, 17629-17634.	1.6	749
4	Role of tissue factor in embryonic blood vessel development. Nature, 1996, 383, 73-75.	13.7	646
5	Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes Journal of Biological Chemistry, 1995, 270, 12607-12613.	1.6	627
6	Vascular Endothelial Growth Factor Induces Endothelial Fenestrations In Vitro. Journal of Cell Biology, 1998, 140, 947-959.	2.3	580
7	Hypoxia-induced Transcriptional Activation and Increased mRNA Stability of Vascular Endothelial Growth Factor in C6 Glioma Cells. Journal of Biological Chemistry, 1995, 270, 19761-19766.	1.6	488
8	Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possibleIn vivo regulatory mechanisms. International Journal of Cancer, 1994, 59, 520-529.	2.3	429
9	Angiopoietin-2 Causes Pericyte Dropout in the Normal Retina: Evidence for Involvement in Diabetic Retinopathy. Diabetes, 2004, 53, 1104-1110.	0.3	306
10	Coordinate expression of vascular endothelial growth factor receptor-1 (fit-1) and its ligand suggests a paracrine regulation of murine vascular development. Developmental Dynamics, 1995, 204, 228-239.	0.8	269
11	Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor 2(flk-1) Are Expressed during Vasculogenesis and Vascular Differentiation in the Quail Embryo. Developmental Biology, 1995, 169, 699-712.	0.9	253
12	Cooperative Interaction of Hypoxia-inducible Factor-2α (HIF-2α) and Ets-1 in the Transcriptional Activation of Vascular Endothelial Growth Factor Receptor-2 (Flk-1). Journal of Biological Chemistry, 2003, 278, 7520-7530.	1.6	239
13	Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nature Cell Biology, 2013, 15, 249-260.	4.6	221
14	Molecular Mechanisms of Developmental and Tumor Angiogenesis. Brain Pathology, 1994, 4, 207-218.	2.1	217
15	Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes, 1998, 47, 401-406.	0.3	211
16	Identification of Vascular Endothelial Growth Factor (VEGF) Receptor-2 (Flk-1) Promoter/Enhancer Sequences Sufficient for Angioblast and Endothelial Cell-Specific Transcription in Transgenic Mice. Blood, 1999, 93, 4284-4292.	0.6	204
17	VEGF Gene Transfer Reduces Intimal Thickening via Increased Production of Nitric Oxide in Carotid Arteries. Human Gene Therapy, 1997, 8, 1737-1744.	1.4	196
18	Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Experimental Cell Research, 2007, 313, 1-9.	1.2	194

#	Article	IF	CITATIONS
19	Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thrombosis and Haemostasis, 2004, 91, 595-605.	1.8	179
20	Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. Journal of Clinical Investigation, 2002, 109, 777-785.	3.9	171
21	De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop. Gastroenterology, 2000, 119, 1358-1372.	0.6	169
22	p38 MAP Kinase—a molecular switch between VEGFâ€induced angiogenesis and vascular hyperpermeability. FASEB Journal, 2003, 17, 262-264.	0.2	159
23	Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Letters, 1995, 358, 311-315.	1.3	150
24	The role of vascular endothelial growth factor in blood vessel formation. Trends in Cell Biology, 1996, 6, 454-456.	3.6	141
25	Identification of Vascular Endothelial Growth Factor (VEGF) Receptor-2 (Flk-1) Promoter/Enhancer Sequences Sufficient for Angioblast and Endothelial Cell-Specific Transcription in Transgenic Mice. Blood, 1999, 93, 4284-4292.	0.6	139
26	Role of SCL/Tal-1, GATA, and Ets transcription factor binding sites for the regulation of Flk-1 expression during murine vascular development. Blood, 2000, 96, 3078-3085.	0.6	136
27	Vascular Endothelial Growth Factor Increases Functional β-Cell Mass by Improvement of Angiogenesis of Isolated Human and Murine Pancreatic Islets. Transplantation, 2005, 79, 1530-1536.	0.5	135
28	Mechanoinduction of lymph vessel expansion. EMBO Journal, 2012, 31, 788-804.	3.5	134
29	Angiogenesis in Embryonic Development—A Review. Placenta, 2000, 21, S11-S15.	0.7	131
30	Insights in Vessel Development and Vascular Disorders Using Targeted Inactivation and Transfer of Vascular Endothelial Growth Factor, the Tissue Factor Receptor, and the Plasminogen System. Annals of the New York Academy of Sciences, 1997, 811, 191-206.	1.8	119
31	Angiogenesis in Embryos and Ischemic Diseases. Thrombosis and Haemostasis, 1997, 78, 678-683.	1.8	115
32	Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. Journal of Clinical Investigation, 2002, 109, 777-785.	3.9	106
33	Multimarker Gene Analysis of Circulating Tumor Cells in Pancreatic Cancer Patients: A Feasibility Study. Oncology, 2012, 82, 3-10.	0.9	104
34	Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathology and Applied Neurobiology, 1999, 25, 104-112.	1.8	100
35	Transforming growth factor-? and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. International Journal of Cancer, 2002, 97, 142-148.	2.3	99
36	Vascular Endothelial Cadherin Promotes Breast Cancer Progression via Transforming Growth Factor β Signaling. Cancer Research, 2008, 68, 1388-1397.	0.4	96

#	Article	IF	CITATIONS
37	Circulating Vascular Progenitor Cells Do Not Contribute to Compensatory Lung Growth. Circulation Research, 2003, 93, 372-379.	2.0	79
38	Cardiomyocyte-specific Prolyl-4-hydroxylase Domain 2 Knock Out Protects from Acute Myocardial Ischemic Injury. Journal of Biological Chemistry, 2011, 286, 11185-11194.	1.6	74
39	Identification of a clonally expanding haematopoietic compartment in bone marrow. EMBO Journal, 2012, 32, 219-230.	3.5	70
40	Hemogenic and nonhemogenic endothelium can be distinguished by the activity of fetal liver kinase (Flk)–1promoter/enhancer during mouse embryogenesis. Blood, 2003, 101, 886-893.	0.6	68
41	Inhibition of hypoxia-inducible factor activity in endothelial cells disrupts embryonic cardiovascular development. Blood, 2006, 107, 584-590.	0.6	68
42	HIF-1α is a protective factor in conditional PHD2-deficient mice suffering from severe HIF-2α–induced excessive erythropoiesis. Blood, 2013, 121, 1436-1445.	0.6	67
43	Inhibition of HIF Prolyl Hydroxylase-2 Blocks Tumor Growth in Mice through the Antiproliferative Activity of TGFβ. Cancer Research, 2011, 71, 3306-3316.	0.4	66
44	Continuous Endothelial Cell Activation Increases Angiogenesis: Evidence for the Direct Role of Endothelium Linking Angiogenesis and Inflammation. Journal of Vascular Research, 2006, 43, 193-204.	0.6	65
45	Neuron-Specific Prolyl-4-Hydroxylase Domain 2 Knockout Reduces Brain Injury After Transient Cerebral Ischemia. Stroke, 2012, 43, 2748-2756.	1.0	65
46	Polyoma Middle T-induced Vascular Tumor Formation: The Role of the Plasminogen Activator/Plasmin System. Journal of Cell Biology, 1997, 137, 953-963.	2.3	65
47	Ablation of cholesterol biosynthesis in neural stem cells increases their VEGF expression and angiogenesis but causes neuron apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8350-8355.	3.3	64
48	Characterization of the Endothelium-Specific Murine Vascular Endothelial Growth Factor Receptor-2 (Flk-1) Promoter. Circulation Research, 1996, 79, 277-285.	2.0	64
49	Adipocyte-Specific Hypoxia-Inducible Factor 2α Deficiency Exacerbates Obesity-Induced Brown Adipose Tissue Dysfunction and Metabolic Dysregulation. Molecular and Cellular Biology, 2016, 36, 376-393.	1.1	63
50	Endothelial cadherins in cancer. Cell and Tissue Research, 2014, 355, 523-527.	1.5	62
51	Loss of Epithelial Hypoxia-Inducible Factor Prolyl Hydroxylase 2 Accelerates Skin Wound Healing in Mice. Molecular and Cellular Biology, 2013, 33, 3426-3438.	1.1	61
52	Type I Collagen Limits VEGFR-2 Signaling by a SHP2 Protein-Tyrosine Phosphatase–Dependent Mechanism 1. Circulation Research, 2006, 98, 45-54.	2.0	55
53	Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. Journal of Translational Medicine, 2012, 10, 222.	1.8	52
54	Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants. International Journal of Cancer, 2004, 111, 348-357.	2.3	48

#	Article	IF	CITATIONS
55	Endothelium-specific Cre recombinase activity in flk-1-Cre transgenic mice. Developmental Dynamics, 2004, 229, 312-318.	0.8	47
56	Functions of the VEGF/VEGF Receptor System in the Vascular System. Seminars in Thrombosis and Hemostasis, 2000, 26, 553-560.	1.5	46
57	Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation. International Journal of Cancer, 2007, 120, 1899-1908.	2.3	44
58	VEGFR2 Signaling Prevents Colorectal Cancer Cell Senescence to Promote Tumorigenesis in Mice With Colitis. Gastroenterology, 2015, 149, 177-189.e10.	0.6	44
59	Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine. Breast Care, 2012, 7, 7-12.	0.8	41
60	HIF prolyl hydroxylase 2 (PHD2) is a critical regulator of hematopoietic stem cell maintenance during steady-state and stress. Blood, 2013, 121, 5158-5166.	0.6	41
61	BIOLOGISTICS AND THE STRUGGLE FOR EFFICIENCY: CONCEPTS AND PERSPECTIVES. International Journal of Modeling, Simulation, and Scientific Computing, 2009, 12, 533-548.	0.9	33
62	Interplay between neural-cadherin and vascular endothelial-cadherin in breast cancer progression. Breast Cancer Research, 2012, 14, R154.	2.2	33
63	Haematopoietic prolyl hydroxylaseâ€1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis. Journal of Pathology, 2017, 241, 547-558.	2.1	32
64	Overexpression of factor inhibiting HIFâ€1 enhances vessel maturation and tumor growth <i>via</i> plateletâ€derived growth factorâ€C. International Journal of Cancer, 2012, 131, E603-13.	2.3	30
65	Thrombopoietin stimulates VECF release from c-Mpl-expressing cell lines and haematopoietic progenitors. FEBS Letters, 1998, 423, 10-14.	1.3	29
66	Upregulation of vascular endothelial growth factor in severe chronic brain hypoxia of the rat. Neuroscience Letters, 1998, 252, 199-202.	1.0	28
67	Receptor tyrosine kinase inhibitors: Are they real tumor killers?. International Journal of Cancer, 2016, 138, 540-554.	2.3	26
68	The expression of VE-cadherin in breast cancer cells modulates cell dynamics as a function of tumor differentiation and promotes tumor–endothelial cell interactions. Histochemistry and Cell Biology, 2018, 149, 15-30.	0.8	24
69	HIF prolyl hydroxylase-2 inhibition diminishes tumor growth through matrix metalloproteinase-induced TGFÎ ² activation. Cancer Biology and Therapy, 2012, 13, 216-223.	1.5	21
70	PHD4 Stimulates Tumor Angiogenesis in Osteosarcoma Cells via TGF-α. Molecular Cancer Research, 2013, 11, 1337-1348.	1.5	20
71	A role for prolyl hydroxylase domain proteins in hippocampal synaptic plasticity. Hippocampus, 2013, 23, 861-872.	0.9	19
72	Design of a Variant of Vascular Endothelial Growth Factor-A (VEGF-A) Antagonizing KDR/Flk-1 and Flt-1. Laboratory Investigation, 2002, 82, 473-481.	1.7	18

#	Article	IF	CITATIONS
73	Angiogenesis in metabolic-vascular disease. Thrombosis and Haemostasis, 2017, 117, 1289-1295.	1.8	17
74	Isolated Pancreatic Islets in Three-Dimensional Matrices are Responsive to Stimulators and Inhibitors of Angiogenesis. Cell Transplantation, 2006, 15, 489-497.	1.2	16
75	Parameter estimation with a novel gradient-based optimization method for biological lattice-gas cellular automaton models. Journal of Mathematical Biology, 2011, 63, 173-200.	0.8	15
76	Hematopoietic hypoxiaâ€inducible factor 2α deficiency ameliorates pathological retinal neovascularization <i>via</i> modulation of endothelial cell apoptosis. FASEB Journal, 2019, 33, 1758-1770.	0.2	15
77	Lymphangiogenesis in Regenerating Tissue. Circulation Research, 2005, 96, 1132-1134.	2.0	14
78	Lentiviral Rescue of Vascular Endothelial Growth Factor Receptor-2 Expression in <i>Flk1</i> â^'/â^' Embryonic Stem Cells Shows Early Priming of Endothelial Precursors. Stem Cells, 2007, 25, 2987-2995.	1.4	14
79	Spatiotemporal Expression of flk-1 in Pulmonary Epithelial Cells during Lung Development. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 163-170.	1.4	14
80	Endothelial Receptor Tyrosine Kinases involved in Blood Vessel Development and Tumor Angiogenesis. Advances in Experimental Medicine and Biology, 2000, 476, 57-66.	0.8	14
81	Development of a molecular multimarker assay for the analysis of circulating tumor cells in adenocarcinoma patients. Clinical Laboratory, 2012, 58, 373-84.	0.2	12
82	Microenvironmentally-driven Plasticity of CD44 isoform expression determines Engraftment and Stem-like Phenotype in CRC cell lines. Theranostics, 2020, 10, 7599-7621.	4.6	11
83	Tracking Adult Neovascularization during Ischemia and Inflammation Using Vegfr2-LacZ Reporter Mice. Journal of Vascular Research, 2008, 45, 437-444.	0.6	10
84	Propanolol and angiogenesis inhibition in hereditary haemorrhagic telangiectasia. Thrombosis and Haemostasis, 2012, 108, 1-2.	1.8	10
85	The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®). International Journal of Oncology, 2014, 45, 2267-2277.	1.4	10
86	In situ Hybridization with RNA Probes. , 1999, 96, 107-117.		8
87	The Influence of VE-Cadherin on Adhesion and Incorporation of Breast Cancer Cells into Vascular Endothelium. International Journal of Molecular Sciences, 2021, 22, 6049.	1.8	8
88	HIF in Vascular Development and Tumour Angiogenesis. Novartis Foundation Symposium, 2007, 283, 126-138.	1.2	6
89	A novel Flk1-TVA transgenic mouse model for gene delivery to angiogenic vasculature. Transgenic Research, 2008, 17, 403-415.	1.3	6
90	PHD3 Acts as Tumor Suppressor in Mouse Osteosarcoma and Influences Tumor Vascularization via PDGF-C Signaling. Cancers, 2018, 10, 496.	1.7	5

#	Article	IF	CITATIONS
91	The Role of Vascular Endothelial Growth Factors and Their Receptors During Embryonic Vascular Development. , 2002, , 21-54.		4
92	Genetic mapping of the vascular endothelial growth factor (Vegf) gene to mouse Chromosome 17. Mammalian Genome, 1997, 8, 451-452.	1.0	3
93	Lack of vascular endothelial growth factor receptor-2/Flk1 signaling does not affect substantia nigra development. Neuroscience Letters, 2013, 553, 142-147.	1.0	3
94	Role of SCL/Tal-1, GATA, and Ets transcription factor binding sites for the regulation of Flk-1 expression during murine vascular development. Blood, 2000, 96, 3078-3085.	0.6	3
95	Angiogenic Growth Factors in Embryos and Tumors. Contributions To Oncology / Beitrage Zur Onkologie, 1992, 44, 224-231.	0.1	2
96	Cellular Automaton Modeling of Tumor Invasion. , 2020, , 851-863.		2
97	Judah Folkman. Thrombosis and Haemostasis, 2008, 99, 250.	1.8	1
98	The role of growth factors in angiogenesis. Journal of Molecular and Cellular Cardiology, 1991, 23, S17.	0.9	0
99	2.W12.5 Adventitial gene transfer to rabbit carotid arteries. Atherosclerosis, 1997, 134, 109-110.	0.4	0
100	De novo expression of vascular endothelial growth factor and its receptors in human pancreatic cancer: Evidence for a novel autocrine mitogenic loop. Gastroenterology, 2000, 118, A447.	0.6	0
101	Lymphangiogenesis in vitro. Blood, 2006, 107, 853-854.	0.6	0
102	Notch, hypoxia and arterial cell fate. Vascular Pharmacology, 2006, 45, 177-178.	1.0	0
103	Heparanase and Thrombin: Common Signalling Pathways in Melanoma Cells?. Thrombosis and Haemostasis, 2018, 118, 1688-1689.	1.8	0
104	In Situ Hybridization Analysis of Vascular Endothelium. , 2004, , 301-312.		0
105	The Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis. , 1998, , 305-318.		0
106	Cellular Automaton Modeling of Tumor Invasion. , 2019, , 1-13.		0

Cellular Automaton Modeling of Tumor Invasion. , 2019, , 1-13. 106